EUCTR2021-001907-33-ES进行中（未招募）1 期
An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial To Evaluate The Efficacy and Safety Of TheraSphere™ followed by Durvalumab (Imfinzi®) With Tremelimumab, Versus TheraSphere™ Alone For Hepatocellular Carcinoma (HCC). - ROWA
Biocompatibles UK Ltd, a wholly owned indirect subsidiary of Boston Scientific Corporation0 个研究点目标入组 150 人开始时间: 2022年5月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Participants must be aged =18 years at the time of screening.
- •2. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and accountability Act in the US, European Union (EU) data privacy regulations in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
- •3. Life expectancy =6 months.
- •4. HCC, diagnosed by radiographic imaging or histology.
- •5. Patient not a candidate for liver resection, thermal ablation, or transplantation at the time of study entry.
- •6. Treatment naïve.
- •7. Measurable disease by mRECIST criteria (e.g. =10mm of enhancement).
- •8. Tumor volume =25% of whole liver volume (determined by imaging).
- •9. Unilobar tumor
- •10. Future liver remnant volume (FLRV) =30% of whole liver volume. FRLV is the volume of liver not planned to be treated with TheraSphere and free of HCC.
- •11. Patients with HBV or HCV infection are to have documented virology status of hepatitis as confirmed by HBV and HCV serology test:
- •a. Patients with HBV infection: HBV DNA load should be =2000 IU/mL obtained within 28 days prior to initiation of study treatment, and Anti-HBV treatment (per local standard of care; e.g., entecavir) for a minimum of 14 days prior to study entry and willingness to continue treatment for the length of the study
- •b. Patients with chronic HCV infection are allowed in the study: for untreated patients, AST/ALT should be =3xULN and for treated patients, antiviral treatment (per local standard of care) should be stopped for a minimum of 14 days prior to study entry and AST/ALT should be =3xULN
- •12. Patient with Human Immunodeficiency Virus (HIV) infection is eligible with well controlled HIV infection, no current or previous AIDS-related complications and CD4+ T-cell (CD4+) counts = 350 cells/uL
- •13. Negative serum pregnancy test in females of child-bearing potential; patients who are breast-feeding cannot participate in this trial.
- •14. Adequate contraception for the patient and his/her sexual partner.
- •15. Adequate renal and marrow function as defined below:
- •a. Hemoglobin =9.0 g/dL
- •b. Absolute neutrophil count =1.5 x 109/L
- •c. Platelet count =75 x 109/L
- •d. Measured or calculated creatinine clearance =45 mL/min as determined by Cockcroft-Gault (using actual body weight)
- •16. Absolute lymphocyte count =1.0 X 109/L
- •17. Adequate liver function, as defined by
- •a. Child-Pugh A
- •b. Serum albumin =30 g/L
- •c. Serum bilirubin <1.1 x the upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert’s syndrome, who will be permitted to enroll in the study in consultation with their physician.
- •d. AST and ALT <3 x ULN.
- •18. Eastern Cooperative Oncology Group (ECOG) performance status of 0 at randomization.
- •19. Body weight >30 kg and BMI =18 kg/m2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any contraindication to angiography or selective visceral catheterization.
- •2. Cone Beam CT or Technetium-99m macroaggregated Albumin hepatic arterial perfusion scintigraphy shows any deposition to the gastrointestinal tract that may not be corrected by angiographic techniques.
- •3. CBCT or 99mTc-MAA hepatic arterial perfusion scintigraphy shows poor tumor targeting that would lead to a dose that does not meet the liver dosing criteria specified in section 9.1, if lobar administration with multi-compartment dosimetry is planned.
- •4. Shunting of blood to the lungs that could result in delivery of >30 Gy to the lungs in a single treatment or >50 Gy cumulative dose to the lungs in case of multiple TheraSphere treatments, as seen on 99mTc-MAA hepatic arterial perfusion scintigraphy.
- •5. Extrahepatic metastases, including patients with hilar/mesenteric/celiac lymph nodes >1.5 cm in shorter axis, or with lung nodules (single lesion, > 1 cm, or multiple smaller lesions with a total diameter >2 cm)
- •6. Brain metastases, leptomeningeal carcinomatosis or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry. Brain metastases will not be recorded as RECIST target lesions at baseline.
- •7. Evidence of any tumor vascular invasion.
- •8. Any prior treatment for HCC including surgery, TACE/TAE, ablation, systemic, and/or radiation treatment (including radiation treatment to the liver for any diagnosis).
- •9. Prior exposure to any immune mediated therapy, including but not limited to other anti PD-1, anti-PDL-1, anti-PDL2, anti-CTLA-4, antibodies, IFN.
- •10. Concurrent treatment for HCC or treatment in the last 4 weeks in another clinical study, unless it is an observational study (non-interventional) or during a non-interventional follow-up stage of an interventional study, or prior randomization to this study
- •11. Hepatic encephalopathy present at study entry and/or episodes of encephalopathy (=Grade 2) within 6 months prior to randomization.
- •12. Presence of ascites, clinical or radiological, trace” of ascites is acceptable.
- •13. HCC with infiltrative disease presentation that is not possible to evaluate by mRECIST.
- •14. History of active primary/acquired immunodeficiency.
- •15. Evidence of pulmonary insufficiency (defined by an arterial oxygen pressure of <60 mmHg, or oxygen saturation of <90% or clinically evident chronic obstructive pulmonary disease.
- •16. Medical history of radiation pneumonitis or recent pneumonitis, regardless of causality
- •17. History of any organ allograft, including bone marrow allo and autograft.
- •18. Active or prior documented autoimmune or inflammatory disorders (including but not limited to, inflammatory bowel disease, SLE, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves’ disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
- •a. Patients with vitiligo or alopecia
- •b. Patients with hypothyroidism (e.g. following Hashimoto’s syndrome) stable on hormone replacement therapy
- •c. Any chronic skin condition that does not require systemic therapy.
- •d. Patients without active disease in the last 5 years may be included but only after consultation with the Sponsor Study physician.
- •e. Patients with celiac disease controlled by diet alone.
- •19. Current or prior use of immunosuppressive medication within 14 days before the first dose of dur
研究者
相似试验
进行中（未招募）
1 期
A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere®/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-upDiabetes mellitus type IIMedDRA version: 9.1 Level: PT Classification code 10012601 Term: Diabetes mellitusEUCTR2006-000305-35-GBMannKind Corporation668
进行中（未招募）
1 期
A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere®/Insulin Versus Subcutaneous Basal Insulin and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow-upEUCTR2006-000306-23-GBMannKind Corporation590
已完成
不适用
A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-Abdominal Infections in Adults-A499 Bacterial infection, unspecifiedBacterial infection, unspecifiedA499PER-063-01MERCK SHARP & DOHME PERU S.R.L.,
已完成
不适用
Ertapenem versus Ceftriaxone and Metronidazole As Treatment For Complicated Intra-abdominal InfectionsComplicated intra-abdominal infectionsInfections and InfestationsOther and unspecified infectious diseasesISRCTN59616541Merck and Co., Inc. (USA)500
Unknown
不适用
A clinical study to check the effect medicine to control the Diarrhea in children.CTRI/2019/06/019838Dr Vijay Yewale